Economic analysis of the ‘Take Charge’ intervention for people following stroke: Results from a randomised trial. Te Ao, B., Harwood, M., Fu, V., Weatherall, M., McPherson, K., Taylor, W. J, McRae, A., Thomson, T., Gommans, J., Green, G., Ranta, A., Hanger, C., Riley, J., & McNaughton, H. Clinical Rehabilitation, August, 2021.
Economic analysis of the ‘Take Charge’ intervention for people following stroke: Results from a randomised trial [link]Paper  doi  abstract   bibtex   2 downloads  
Objective: To undertake an economic analysis of the Take Charge intervention as part of the Taking Charge after Stroke (TaCAS) study. Design: An open, parallel-group, randomised trial comparing active and control interventions with blinded outcome assessment Setting: Community. Participants: Adults ( n = 400) discharged to community, non-institutional living following acute stroke. Interventions: The Take Charge intervention, a strengths based, self-directed rehabilitation intervention, in two doses (one or two sessions), and a control intervention (no Take Charge sessions). Measures: The cost per quality-adjusted life year (QALY) saved for the period between randomisation (always post hospital discharge) and 12 months following acute stroke. QALYs were calculated from the EuroQol-5D-5L. Costs of stroke-related and non-health care were obtained by questionnaire, hospital records and the New Zealand Ministry of Health. Results: One-year post hospital discharge cost of care was mean (95% CI) $US4706 (3758–6014) for the Take Charge intervention group and $6118 (4350–8005) for control, mean (95% CI) difference $ −1412 (−3553 to +729). Health utility scores were mean (95% CI) 0.75 (0.73–0.77) for Take Charge and 0.71 (0.67–0.75) for control, mean (95% CI) difference 0.04 (0.0–0.08). Cost per QALY gained for the Take Charge intervention was $US −35,296 (=£ −25,524, € −30,019). Sensitivity analyses confirm Take Charge is cost-effective, even at a very low willingness-to-pay threshold. With a threshold of $US5000 per QALY, the probability that Take Charge is cost-effective is 99%. Conclusion: Take Charge is cost-effective and probably cost saving.
@article{te_ao_economic_2021,
	title = {Economic analysis of the ‘{Take} {Charge}’ intervention for people following stroke: {Results} from a randomised trial},
	issn = {0269-2155, 1477-0873},
	shorttitle = {Economic analysis of the ‘{Take} {Charge}’ intervention for people following stroke},
	url = {http://journals.sagepub.com/doi/10.1177/02692155211040727},
	doi = {10.1177/02692155211040727},
	abstract = {Objective:
              To undertake an economic analysis of the Take Charge intervention as part of the Taking Charge after Stroke (TaCAS) study.
            
            
              Design:
              An open, parallel-group, randomised trial comparing active and control interventions with blinded outcome assessment
            
            
              Setting:
              Community.
            
            
              Participants:
              Adults ( n = 400) discharged to community, non-institutional living following acute stroke.
            
            
              Interventions:
              The Take Charge intervention, a strengths based, self-directed rehabilitation intervention, in two doses (one or two sessions), and a control intervention (no Take Charge sessions).
            
            
              Measures:
              The cost per quality-adjusted life year (QALY) saved for the period between randomisation (always post hospital discharge) and 12 months following acute stroke. QALYs were calculated from the EuroQol-5D-5L. Costs of stroke-related and non-health care were obtained by questionnaire, hospital records and the New Zealand Ministry of Health.
            
            
              Results:
              One-year post hospital discharge cost of care was mean (95\% CI) \$US4706 (3758–6014) for the Take Charge intervention group and \$6118 (4350–8005) for control, mean (95\% CI) difference \$ −1412 (−3553 to +729). Health utility scores were mean (95\% CI) 0.75 (0.73–0.77) for Take Charge and 0.71 (0.67–0.75) for control, mean (95\% CI) difference 0.04 (0.0–0.08). Cost per QALY gained for the Take Charge intervention was \$US −35,296 (=£ −25,524, € −30,019). Sensitivity analyses confirm Take Charge is cost-effective, even at a very low willingness-to-pay threshold. With a threshold of \$US5000 per QALY, the probability that Take Charge is cost-effective is 99\%.
            
            
              Conclusion:
              Take Charge is cost-effective and probably cost saving.},
	language = {en},
	urldate = {2021-09-09},
	journal = {Clinical Rehabilitation},
	author = {Te Ao, Braden and Harwood, Matire and Fu, Vivian and Weatherall, Mark and McPherson, Kathryn and Taylor, William J and McRae, Anna and Thomson, Tom and Gommans, John and Green, Geoff and Ranta, Annemarei and Hanger, Carl and Riley, Judith and McNaughton, Harry},
	month = aug,
	year = {2021},
	pages = {026921552110407},
}

Downloads: 2